About
About Hyundai Pharmaceutical Co., Ltd
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilatory, dermatological agent, dermatology, dietary supplements, digestive system, endocrine system, expectorants, eye tonic and vitamins, gynaecolog antifungals, gynaecologic antiseptics, hemostatics, labour inhibitors, leukotriene modulator, narcotic analgesics, NSAIDs, oestrogens, ophthalmic products, OTH.sex horm and similar, SERMS, systemic hormonal contraceptives, urogenital system depilatory, uterotonic products, various alimentary tract and metabolism products, vitamins, acne, allergy, alopecia treatment, analgesics and anti-inflammatory, anemia, antimicrobial and antivirus, arthritis, contraceptives, dermatological agent, diagnostic reagent, gastrointestinal disorder and digestant, lip care, nutrition, ophthalmic product, respiratory, urogenital system, wound healing, and others. Hyundai Pharmaceutical Co., Ltd. was founded in 1965 and is headquartered in Seoul, South Korea.
Visit company website
5 years, 5 months ago
Hyundai Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 1.3% above its 200 day moving average.
From a valuation standpoint, the stock is 82.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.5.
Hyundai Pharmaceutical Co., Ltd's total revenue rose by 4.4% to $33B since the same quarter in the previous year.
Its net income has increased by 146.0% to $48M since the same quarter in the previous year.
Finally, its free cash flow grew by 401.3% to $4B since the same quarter in the previous year.
Based on the above factors, Hyundai Pharmaceutical Co., Ltd gets an overall score of 5/5.